Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CDX-0158 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CDX-0158 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CDX-0158 (formerly known as KTN-0158) | BIOLOGICAL | Single agent CDX-0158 until unacceptable toxicity or progressive disease |
Inclusion Criteria: 1. Written informed consent and any locally required authorization (eg, HIPAA) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations. 2. Metastatic or unresectable cancer that expresses KIT as document...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
CDX-0158 is an investigational monoclonal antibody being developed for the treatment of advanced cancer. It is intended for adult patients with advanced solid tumors. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
CDX-0158 is being developed by Celldex Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CLDX. The company is conducting clinical research to evaluate the safety and pharmacokinetics of this investigational therapy.
CDX-0158 is in Phase 1 clinical development. A Phase 1 study has been completed, evaluating the safety and pharmacokinetics of the drug in adult patients with advanced solid tumors. The drug remains investigational and is not yet approved for any use.
CDX-0158 has one completed clinical trial, registered under NCT02642016. This Phase 1 study evaluated the safety and pharmacokinetics of CDX-0158 in 28 adult patients with advanced solid tumors in the United States. The trial was uncontrolled and not randomized or blinded.
No alternative names for CDX-0158 have been disclosed. The drug is identified solely by its code name CDX-0158 in clinical trial registrations and development documentation.